关键词: 卵巢肿瘤, 早期诊断, 肿瘤标记, 生物学, 循环肿瘤细胞

Abstract: Liquid biopsy (LB), as a new generation detection technology, can more accurately evaluate the disease progress of tumor patients and become a valuable management tool of clinical medicine, which is expected to improve outcome of ovarian malignant tumor. It can be used in early screening, curative effect, assessing drug-resistance, relapse and prognosis of ovarian cancer via monitoring quantity changes of circulating tumor cells (CTCs) in body fluid. Comparing present clinical strategy depended on tumor markers, CTCs exhibit higher specificity and can be cytologically analyzed and cultured. However, the relationship between CTCs and the disease progression of ovarian tumors is not yet clear. Besides, more advanced molecular enrichment strategies needs to be applied to ovarian CTCs.

Key words: Ovarian neoplasms, Early diagnosis, Tumor markers, biological, Circulating tumor cells